Patent 11129829 was granted and assigned to Skyhawk Therapeutics on September, 2021 by the United States Patent and Trademark Office.
Described herein are methods of use of small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.